Leavell Investment Management Inc. Lowers Position in Becton Dickinson and Co (BDX)

Leavell Investment Management Inc. trimmed its position in shares of Becton Dickinson and Co (NYSE:BDX) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,614 shares of the medical instruments supplier’s stock after selling 540 shares during the period. Leavell Investment Management Inc.’s holdings in Becton Dickinson and were worth $3,342,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in BDX. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Becton Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 240 shares in the last quarter. Harfst & Associates Inc. boosted its stake in shares of Becton Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares in the last quarter. Harvest Fund Management Co. Ltd boosted its stake in shares of Becton Dickinson and by 82.8% in the 2nd quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock valued at $146,000 after purchasing an additional 338 shares in the last quarter. Acrospire Investment Management LLC boosted its stake in shares of Becton Dickinson and by 259.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 831 shares of the medical instruments supplier’s stock valued at $162,000 after purchasing an additional 600 shares in the last quarter. Finally, Valeo Financial Advisors LLC acquired a new stake in Becton Dickinson and during the 3rd quarter worth approximately $191,000. Hedge funds and other institutional investors own 75.69% of the company’s stock.

Shares of Becton Dickinson and Co (NYSE:BDX) opened at $237.11 on Friday. Becton Dickinson and Co has a one year low of $175.66 and a one year high of $248.39. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03. The firm has a market cap of $54,390.00, a price-to-earnings ratio of 50.99, a PEG ratio of 1.73 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.03. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The business had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter last year, the firm posted $2.12 EPS. Becton Dickinson and’s revenue was down 2.0% compared to the same quarter last year. analysts expect that Becton Dickinson and Co will post 10.92 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.27%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s payout ratio is currently 64.52%.

Several equities research analysts recently commented on BDX shares. Wells Fargo & Co reiterated a “positive” rating and set a $235.00 target price (up from $225.00) on shares of Becton Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Argus lifted their target price on shares of Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. KeyCorp started coverage on shares of Becton Dickinson and in a research report on Friday, January 5th. They set an “overweight” rating and a $260.00 target price on the stock. Bank of America restated a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a report on Friday, January 19th. Finally, Morgan Stanley raised their price target on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $233.80.

TRADEMARK VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/03/becton-dickinson-and-co-bdx-shares-sold-by-leavell-investment-management-inc.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply